Fulranumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | NGF |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 902141-80-4  |
| ChemSpider | none |
| UNII | 0E986JU40I  |
| Chemical and physical data | |
| Formula | C6446H9930N1718O2018S50 |
| Molar mass | 145.39 kg/mol |
| (what is this?) (verify) |
Fulranumab is a monoclonal antibody against nerve growth factor.[1] It was designed for the treatment of pain.[2]
Johnson & Johnson licensed the drug from Amgen in a deal valued at around USD 425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.[3]
References[edit]
- ^ http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm301305.pdf
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab" (PDF). American Medical Association.
- ^ http://www.pmlive.com/pharma_news/j_and_j_drops_ngf_blocker_fulranumab_968433
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
